.jpeg)
{{ variable.name }}
Opicapone is a peripherally selective, reversible catechol-O-methyltransferase (COMT) inhibitor. By inhibiting COMT enzyme activity, it reduces the peripheral metabolism of levodopa, thereby prolonging its action time and enhancing its efficacy.
1. Generic name: Opicapone (Opicapone)
2. Trade name: ONGENTYS®
3. English name: Opicap oneCapsules
Opicapone is a catechol-O-methyltransferase (COMT) inhibitor, used as an adjuvant treatment with levodopa/carbidopa, and is suitable for "off-phase" attacks in patients with Parkinson's disease (PD).
25mg capsule: Light blue opaque cap and light pink opaque body, with blue "OPC" and "25" printed on the cap and body.
1. The active ingredient in each capsule is Opicapone.
2. Inactive ingredients include: lactose, magnesium stearate, pregelatinized starch, and sodium hydroxypropyl starch. The capsule shell contains: FD&C Blue No. 2, FD&C Red No. 3, gelatin, and titanium dioxide.
1. The recommended dose is 50 mg once a day, taken orally before going to bed.
2. Avoid eating within 1 hour before and after taking the medicine.
1. The recommended dose for patients with moderate hepatic insufficiency (Child-Pugh Class B) is 25 mg, taken once a day before going to bed.
2. Patients with severe hepatic insufficiency (Child-Pugh C class) should avoid use.
3. Patients with end-stage renal disease (CLcr<15mL/min) should also avoid use. No dose adjustment is required in patients with mild to moderate renal impairment.
1. Dietary requirements: Fasting within 1 hour before and after taking the medication.
2. Treatment of missed doses: If you miss a dose, take the regular dose at the original time the next day, and there is no need to make up for it.
3. Vomiting treatment: Not clearly stated, it is recommended to consult a doctor.
4. Medication discontinuation method: Patient symptoms should be monitored when discontinuing medication, and the dosage of other dopaminergic drugs should be adjusted if necessary.
1. Pregnant women:Based on animal data, it may cause harm to the fetus and should be used with caution.
2. Breastfeeding women: There is no human data. It is recommended to decide whether to use it after weighing the pros and cons.
3. Children: Safety and effectiveness have not been established.
4. Elderly people: There is no need to adjust the dosage, but please note that they may be more sensitive to adverse reactions.
1. The most common adverse reactions (incidence rate ≥4% and higher than placebo) include: Dyskinesia, constipation, elevated blood creatine kinase, hypotension/syncope, and weight loss.
2. Other serious adverse reactions include: Daytime drowsiness, hallucinations, impulse control disorders, high fever and confusion after drug withdrawal.
1. It is prohibited to use it in combination with non-selective monoamine oxidase inhibitors (MAOIs).
2. It is prohibited to be used in patients with a history of pheochromocytoma, paraganglioma or other catecholamine-secreting tumors.
1. Combined use with non-selective MAOIs can lead to an increase in catecholamine levels and increase cardiovascular risk.
2. When used in combination with drugs metabolized by COMT (such as isoproterenol, epinephrine, etc.), changes in heart rate, rhythm and blood pressure need to be monitored.
Storage temperature should be below 30°C (86°F).